PMC:7283670 / 76900-77260 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T168","span":{"begin":149,"end":153},"obj":"Body_part"},{"id":"T169","span":{"begin":167,"end":171},"obj":"Body_part"}],"attributes":[{"id":"A168","pred":"uberon_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"A169","pred":"uberon_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/UBERON_0000025"}],"text":"Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T661","span":{"begin":149,"end":153},"obj":"http://purl.obolibrary.org/obo/UBERON_0000025"},{"id":"T662","span":{"begin":167,"end":171},"obj":"http://purl.obolibrary.org/obo/UBERON_0000025"}],"text":"Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T311","span":{"begin":28,"end":33},"obj":"Chemical"}],"attributes":[{"id":"A311","pred":"chebi_id","subj":"T311","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020"}

{"project":"LitCovid-sentences","denotations":[{"id":"T691","span":{"begin":0,"end":360},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1931","span":{"begin":259,"end":271},"obj":"Species"}],"attributes":[{"id":"A1931","pred":"tao:has_database_id","subj":"1931","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020"}